Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 1 , Pages 1-14 , March 2006

Lessons learnt from structural studies of the oestrogen receptor

  • Ashley C.W. Pike, BSc, PhD (Wellcome Trust Career Development Fellow)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 1904 328271; Fax: +44 1904 328266.

References 

  1. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiological Reviews. 2001;81:1535–1565
  2. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 2002;108:465–474
  3. Dodds EC, Goldberg L, Lawson W, Robinson R. Oestrogenic activity of certain synthetic compounds. Nature. 1938;141:247–249
  4. Jordan VC, Mittal S, Gosden B, et al. Structure activity relationships of estrogens. Environmental Health Perspectives. 1985;61:97–110
  5. Anstead GM, Carlson KE, Katzenellenbogen JA. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids. 1997;62:268–303
  6. Katzenellenbogen JA, Muthyala R. Interactions of exogenous endocrine active substances with nuclear receptors. Pure and Applied Chemistry. 2003;75:1797–1817
  7. Fang H, Tong W, Shi LM, et al. Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chemical Research in Toxicology. 2001;14:280–294
  8. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240:889–895
  9. Khorasanizadeh S, Rastinejad F. Nuclear-receptor interactions on DNA-response elements. Trends in Biochemical Sciences. 2001;26:384–390
  10. Claessens F, Gewirth DT. DNA Recognition by Nuclear receptors. Essays in Biochemistry: Nuclear Receptor Superfamily. London: Portland Press Ltd; 2004;p. 59–72
  11. Li Y, Lambert MH, Xu HE. Activation of nuclear receptors: a perspective from structural genomics. Structure. 2003;11:741–746
  12. Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligand-binding domains three-dimensional structures, molecular interactions and pharmacological implications. Trends in Pharmacological Sciences. 2000;21:381–388
  13. Greschik I, Moras D. Structure-activity relationship of nuclear receptor–ligand interactions. Current Topics in Medicinal Chemistry. 2003;3:1573–1599
  14. Nagy L, Schwabe JWR. Mechanism of the nuclear receptor molecular switch. Trends in Biochemical Sciences. 2004;29:317–324
  15. Nettles KW, Greene GL. Ligand control of coregulator recruitment to nuclear receptors. Annual Review of Physiology. 2005;67:309–333
  16. Brzozowski AM, Pike ACW, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389:753–758
  17. Tanenbaum DM, Wang Y, Williams SP, Sigler PB. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proceedings of the National Academy of Sciences of the USA. 1998;95:5998–6003
  18. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95:927–937
  19. Pike ACW, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. The EMBO Journal. 1999;18:4608–4618
  20. Pike ACW, Brzozowski AM, Walton J, et al. Structural insights into the mode of action of a pure antiestrogen. Structure. 2001;9:145–153
  21. Wurtz JM, Bourguet W, Renaud JP, et al. A canonical structure for the ligand-binding domain of nuclear receptors. Nature Structural Biology. 1996;3:87–94
  22. Wärnmark A, Treuter E, Gustafsson J-Å, et al. Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. The Journal of Biological Chemistry. 2002;277:21862–21868
  23. Nolte RT, Wisely GB, Westin S, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998;395:137–143
  24. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacological Reviews. 1998;50:151–196
  25. McDonnell DP, Connor CE, Wijayaratne A, et al. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Recent Progress in Hormone Research. vol. 57. Bethesda: Endocrine Soc; 2002;p. 295–316
  26. Meegan MJ, Lloyd DG. Advances in the science of estrogen receptor modulation. Current Medicinal Chemistry. 2003;10:181–210
  27. Renaud J, Bischoff SF, Buhl T, et al. Estrogen receptor modulators: identification and structure–activity relationships of potent ER alpha-selective tetrahydroisoquinoline ligands. Journal of Medicinal Chemistry. 2003;46:2945–2957
  28. Blizzard TA, DiNinno F, Morgan JD, et al. Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers. Bioorganic and Medicinal Chemistry Letters. 2005;15:107–113
  29. Shiau AK, Barstad D, Radek JT, et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nature Structural Biology. 2002;9:359–364
  30. Manas ES, Xu ZB, Unwalla RJ, Somers WS. Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods. Structure. 2004;12:2197–2207
  31. Webb P, Nguyen P, Kushner PJ. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo. The Journal of Biological Chemistry. 2003;278:6912–6920
  32. Huang HJ, Norris JD, McDonnell DP. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for compressors in regulating cellular responses to agonists and antagonists. Molecular Endocrinology. 2002;16:1778–1792
  33. Wu YL, Yang X, Ren Z, et al. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Molecular Cell. 2005;18:413–424
  34. Hu X, Lazar MA. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature. 1999;402:93–96
  35. Xu HE, Stanley TB, Montana VG, et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR alpha. Nature. 2002;415:813–817
  36. Lavinsky RM, Jepsen K, Heinzel T, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proceedings of the National Academy of Sciences of the USA. 1998;95:2920–2925
  37. Shang YF, Hu X, DiRenzo J, et al. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000;103:843–852
  38. Shang YF, Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 2002;295:2465–2468
  39. Jung D-J, Lee S-K, Lee JW. Agonist-dependent repression mediated by mutant estrogen receptor alpha that lacks the activation function 2 core domain. The Journal of Biological Chemistry. 2001;276:37280–37283
  40. Paige LA, Christensen DJ, Gron H, et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proceedings of the National Academy of Sciences of the USA. 1999;96:3999–4004
  41. Wijayaratne AL, Nagel SC, Paige LA, et al. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology. 1999;140:5828–5840
  42. Iannone MA, Simmons CA, Kadwell SH, et al. Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. Molecular Endocrinology. 2004;18:1064–1081
  43. Sumbayev VV, Bonefeld-Jorgensen EC, Wind T, Andreasen PA. A novel pesticide-induced conformational state of the oestrogen receptor ligand-binding domain, detected by conformation- specific peptide binding. FEBS Letters. 2005;579:541–548
  44. Ekena K, Katzenellenbogen JA, Katzenellenbogen BS. Determinants of ligand specificity of estrogen receptor-alpha: estrogen versus androgen discrimination. The Journal of Biological Chemistry. 1998;273:693–699
  45. Thornton JW. Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proceedings of the National Academy of Sciences of the USA. 2001;98:5671–5676
  46. Manas ES, Unwalla RJ, Xu ZB, et al. Structure-based design of estrogen receptor-beta selective ligands. Journal of the American Chemical Society. 2004;126:15106–15119
  47. Malamas MS, Manas ES, McDevitt RE, et al. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. Journal of Medicinal Chemistry. 2004;47:5021–5040
  48. Kuiper GGJM, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138:863–870
  49. Nettles KW, Sun J, Radek JT, et al. Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Molecular Cell. 2004;13:317–327
  50. Katzenellenbogen JA, Muthyala R, Katzenellenbogen BS. Nature of the ligand-binding pocket of estrogen receptor alpha and beta: the search for subtype-selective ligands and implications for the prediction of estrogenic activity. Pure and Applied Chemistry. 2003;75:2397–2403
  51. Renaud J, Bischoff SF, Buhl T, et al. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure–activity relationship of ER alpha-selective tetrahydroisoquinoline ligands. Journal of Medicinal Chemistry. 2005;48:364–379
  52. Kim S, Wu JY, Birzin ET, et al. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators. Journal of Medicinal Chemistry. 2004;47:2171–2175
  53. Tan Q, Blizzard TA, Morgan JD, et al. Estrogen receptor ligands. Part 10: chromanes: old scaffolds for new SERAMs. Bioorganic and Medicinal Chemistry Letters. 2005;15:1675–1681
  54. Henke BR, Consler TG, Go N, et al. A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta. Journal of Medicinal Chemistry. 2002;45:5492–5505
  55. Miller CP, Collini MD, Harris HA. Constrained phytoestrogens and analogues as ER beta selective ligands. Bioorganic and Medicinal Chemistry Letters. 2003;13:2399–2403
  56. Kuiper G, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139:4252–4263
  57. Adlercreutz H. Phyto-oestrogens and cancer. The Lancet Oncology. 2002;3:364–373
  58. Oostenbrink BC, Pitera JW, van Lipzig MMH, et al. Simulations of the estrogen receptor ligand-binding domain: affinity of natural ligands and xenoestrogens. Journal of Medicinal Chemistry. 2000;43:4594–4605
  59. van Lipzig MMH, ter Laak AM, Jongejan A, et al. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method. Journal of Medicinal Chemistry. 2004;47:1018–1030
  60. Yoon S, Welsh WJ. Identification of a minimal subset of receptor conformations for improved multiple conformation docking and two-step scoring. Journal of Chemical Information and Computer Sciences. 2004;44:88–96
  61. Gangloff M, Ruff M, Eiler S, et al. Crystal structure of a mutant hER alpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. The Journal of Biological Chemistry. 2001;276:15059–15065
  62. Eiler S, Gangloff M, Duclaud S, et al. Overexpression, purification, and crystal structure of native ER alpha LBD. Protein Expression and Purification. 2001;22:165–173
  63. Leduc AM, Trent JO, Wittliff JL, et al. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proceedings of the National Academy of Sciences of the USA. 2003;100:11273–11278
  64. Kong EH, Heldring N, Gustafsson JA, et al. Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proceedings of the National Academy of Sciences of the USA. 2005;102:3593–3598
  65. Esnouf RM. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. Journal of Molecular Graphics and Modelling. 1997;15:132–137
  66. Merritt EA, Bacon DJ. Raster3D: photorealistic molecular graphics. Methods in Enzymology. 1997;277:505–524

PII: S1521-690X(05)00069-2

doi: 10.1016/j.beem.2005.09.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 1 , Pages 1-14 , March 2006

Article Tools

* Image Usage & Resolution